Currently, a 750mcg teriparatide injection product is accessible in Australia but its access is conditional. Usually , it’s dispensed for patients with debilitating osteoporosis who exhibit an failure to respond adequately to, or cannot tolerate, conventional therapies. Regarding cost can fluctuate